Catalyst Capital Advisors LLC Has $332,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Catalyst Capital Advisors LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 132.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 637 shares of the medical equipment provider’s stock after purchasing an additional 363 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in Intuitive Surgical were worth $332,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in Intuitive Surgical by 1.4% in the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock valued at $7,393,673,000 after acquiring an additional 210,363 shares during the last quarter. FMR LLC lifted its stake in Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after acquiring an additional 838,793 shares during the last quarter. Geode Capital Management LLC lifted its stake in Intuitive Surgical by 1.9% in the third quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock valued at $3,677,194,000 after acquiring an additional 143,440 shares during the last quarter. Fisher Asset Management LLC lifted its stake in Intuitive Surgical by 1.8% in the third quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider’s stock valued at $2,349,441,000 after acquiring an additional 86,208 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its stake in Intuitive Surgical by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock valued at $1,890,676,000 after acquiring an additional 24,183 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $595.55 on Tuesday. The firm has a market capitalization of $212.12 billion, a PE ratio of 92.91, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39. The company’s fifty day moving average price is $559.48 and its two-hundred day moving average price is $520.19. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00.

Insider Buying and Selling at Intuitive Surgical

In other news, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,348 shares of company stock valued at $3,587,582 in the last 90 days. 0.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ISRG shares. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. UBS Group lifted their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Barclays boosted their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Bernstein Bank boosted their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.